The gene-editing drug VERVE-102 has demonstrated safety and efficacy in reducing bad cholesterol by 62% in a small Phase I trial involving 35 patients. The findings suggest potential long-term benefits in lowering cardiovascular disease risk, although further data is needed for conclusive results.
Our neutral summary
The gene-editing drug VERVE-102 has demonstrated safety and efficacy in reducing bad cholesterol by 62% in a small Phase I trial involving 35 patients. The findings suggest potential long-term benefits in lowering cardiovascular disease risk, although further data is needed for conclusive results.
The reporting belongs to Ars Technica; we don't reproduce it.
No note attached
on this article.
Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial
Gene-editing drug VERVE-102 shows promise in reducing bad cholesterol in early trial